omniture
logo
Search
南京驯鹿医疗技术有限公司
Media Room

Photo News

rss
IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

2025-10-29 17:01 899
Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

2025-10-22 19:39 1262
Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis

Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis

2025-10-16 20:45 1379
2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment

2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment

2025-09-19 09:39 1981
IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH

2024-12-10 10:00 2302
IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment

IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment

2024-09-30 13:48 1715
IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting

IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting

2024-09-27 15:41 1754
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies

Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies

2022-11-21 21:00 2928
IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder

IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder

2022-10-11 19:00 2231